Zacks: Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) Given $13.75 Average Price Target by Brokerages

Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) has earned a consensus broker rating score of 1.25 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company. Osmotica Pharmaceuticals’ rating score has improved by 6% in the last 90 days as a result of a number of analysts’ ratings changes.

Brokers have set a 12 month consensus target price of $13.75 for the company and are predicting that the company will post ($0.04) EPS for the current quarter, according to Zacks. Zacks has also assigned Osmotica Pharmaceuticals an industry rank of 51 out of 256 based on the ratings given to its competitors.

A number of analysts have weighed in on OSMT shares. Zacks Investment Research raised shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research report on Tuesday. Barclays reissued a “hold” rating on shares of Bank of Montreal in a research report on Tuesday, June 11th. Finally, Wells Fargo & Co set a $14.00 target price on shares of Osmotica Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, March 28th.

NASDAQ:OSMT traded down $0.04 on Monday, reaching $3.58. 81,450 shares of the stock traded hands, compared to its average volume of 139,513. The stock has a market capitalization of $186.51 million and a price-to-earnings ratio of -7.02. The firm has a 50 day moving average of $3.27. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.70 and a quick ratio of 1.41. Osmotica Pharmaceuticals has a 1-year low of $2.20 and a 1-year high of $9.90.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last released its earnings results on Thursday, May 9th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.08). The business had revenue of $57.13 million for the quarter, compared to analyst estimates of $53.58 million. On average, sell-side analysts predict that Osmotica Pharmaceuticals will post -0.25 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. American International Group Inc. bought a new position in shares of Osmotica Pharmaceuticals during the 4th quarter worth approximately $50,000. SG Americas Securities LLC bought a new position in shares of Osmotica Pharmaceuticals during the 1st quarter worth approximately $45,000. Deutsche Bank AG bought a new position in shares of Osmotica Pharmaceuticals during the 4th quarter worth approximately $111,000. Northern Trust Corp bought a new position in shares of Osmotica Pharmaceuticals during the 4th quarter worth approximately $615,000. Finally, Geode Capital Management LLC bought a new position in shares of Osmotica Pharmaceuticals during the 4th quarter worth approximately $668,000. Hedge funds and other institutional investors own 11.64% of the company’s stock.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Further Reading: How to track put option volume

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.